Estrogen metabolism genotypes, use of long-term hormone replacement therapy and risk of postmenopausal breast cancer

Oncology Reports

Volumn 26, Issue 2, 2011, Pages 479-485

  Cerne, Jasmina Ziva ^a   Novakovic, Srdjan ^b   Frkovic Grazio, Snjezana ^b   Pohar Perme, Maja ^c   Stegel, Vida ^b   Gersak, Ksenija ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b INSTITUTE OF ONCOLOGY   (Slovenia)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Association study; Breast cancer; Estrogen metabolism; Hormone replacement therapy use; Polymorphisms

Indexed keywords

CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1B1; DNA; ESTROGEN; GESTAGEN; GLUTATHIONE TRANSFERASE P1; MANGANESE SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ESTROGEN METABOLISM; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEALTH SURVEY; HOMOZYGOTE; HORMONE SUBSTITUTION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; POSTMENOPAUSE BREAST CANCER; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TREATMENT DURATION; WILD TYPE;

AGED; AGED, 80 AND OVER; ARYL HYDROCARBON HYDROXYLASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; ESTROGENS; FEMALE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POSTMENOPAUSE; RISK FACTORS; SUPEROXIDE DISMUTASE;

EID: 79958216099     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1298     Document Type: Article

References (27)

1. Yager JD and Davidson NE: Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282, 2006.
2. Yue W, Santen RJ, Wang JP, et al: Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol-induced carcinogenesis. J Steroid Biochem Mol Biol 86: 477-486, 2003. (Pubitemid 37412587)
3. Rogan EG, Badawi AF, Devanesan PD, et al: Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 24: 697-702, 2003. (Pubitemid 36592404)
4. Cavalieri E, Frenkel K, Liehr JG, Rogan E and Roy D: Estrogens as endogenous genotoxic agents - DNA adducts and mutation. J NCI Monogr 27: 75-93, 2000.
5. Pharoah PD, Tyrer J, Dunning AM, Easton DF and Ponder BA: Association between common variation in 120 candidate genes and breast cancer risk. PLoS Genet 3: e42, 2007.
6. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer: Collaborative group on hormonal factors in breast cancer. Lancet 350: 1047-1059, 1997.
7. Fournier A, Berrino F, Riboli E, Avenel V and Clavel-Chapelon F: Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer 114: 448-454, 2005. (Pubitemid 40279968)
8. Beral V: Million women study collaborators. Breast cancer and hormone-replacement therapy in the million women study. Lancet 362: 419-427, 2003.
9. Speroff L: The million women study and breast cancer. Maturitas 46: 1-6, 2003.
10. Anderson GL, Limacher M, Assaf AR, et al: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712, 2004. (Pubitemid 38489892)
11. Finley C, Gregg EV, Solomon LJ and Gay E: Disparities in hormone replacement therapy use by socioeconomic status in a primary care population. J Community Health 26: 39-50, 2001. (Pubitemid 33638551)
12. Mitrunen K and Hirvonen A: Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 544: 9-41, 2003.
13. Thompson PA and Ambrosone C: Molecular epidemiology of genetic polymorphisms in estrogen metabolizing enzymes in human breast cancer. J Natl Cancer Inst Monogr 27: 125-134, 2000.
14. Colhoun HM, McKeigue PM and Davey Smith G: Problems of reporting genetic associations with complex outcomes. Lancet 361: 865-872, 2003. (Pubitemid 36331853)
15. Low YL, Dunning AM, Dowsett M, et al: Implications of gene-environment interaction in studies of gene variants in breast cancer: an example of dietary isoflavones and the D356N polymorphism in the sex hormone-binding globulin gene. Cancer Res 66: 8980-8983, 2006. (Pubitemid 44521115)
16. Wang S, Wang F, Shi X, et al: Association between manganese superoxide dismutase (MnSOD) Val-9Ala polymorphism and cancer risk - A meta-analysis. Eur J Cancer 45: 2874-2881, 2009.
17. Tamimi RM, Hankinson SE, Spiegelman D, Colditz GA and Hunter DJ: Manganese superoxide dismutase polymorphism, plasma antioxidants, cigarette smoking, and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 13: 989-996, 2004. (Pubitemid 38756709)
18. Rosenblum JS, Gilula N and Lerner RA: On signal sequence polymorphisms and disease of distribution. Proc Natl Acad Sci USA 93: 4471-4473, 1996. (Pubitemid 26144310)
19. Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D and Degoul F: The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics 13: 145-157, 2003. (Pubitemid 36324244)
20. Ambrosone CB, Freudenheim JL, Thompson PA, et al: Manganese superoxide dismutase (MnSOD) genetic polymorphism, dietary antioxidants, and risk of breast cancer. Cancer Res 59: 602-606, 1999. (Pubitemid 29076057)
21. Mitrunen K, Sillanpaa P, Kataja V, et al: Association between manganese superoxide dismutase (MnSOD) gene polymorphism and breast cancer risk. Carcinogenesis 22: 827-829, 2001. (Pubitemid 32447933)
22. Bag A and Bag N: Target sequence polymorphism of human manganese superoxide dismutase gene and its association with cancer risk: A review. Cancer Epidemiol Biomarkers Prev 17: 3298-3305, 2008.
23. 2. Antioxid Redox Signal 8: 1295-1305, 2006. (Pubitemid 44182428)
24. 2-mediated ERK1/2 activation. J Biol Chem 276: 14264-14270, 2001.
25. Rebbeck TR, Troxel AB, Shatalova G, et al: Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk Cancer Epidemiol Biomarkers Prev 16: 1318-1320, 2007.
26. Diergaarde B, Potter JD, Jupe ER, et al: Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev 17: 1751-1759, 2008.
27. Marie-Genica consortium on genetic susceptibility for menopausal hormone therapy-related breast cancer risk. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat 119: 463-467, 2010.